Introduction
============

As a common mental disorder, depression is estimated to affect 350 million people in the world by 2030 ([@B22]). Conventional medicines for many depressed patients address only low efficacy but with untoward side effects ([@B2]). Chinese herbs have a very long history for the use in the treatment of depression with few side effects reported. Extract of Radix Polygalae (the root of Polygala tenuifolia Willd) has been used as an antidepressant, a tranquilizer and an antipsychotic agent in the past several years ([@B3]; [@B14]; [@B19]). 3,6'-Disinapoyl sucrose (DISS) and tenuifoliside A (TFSA) are the principle active ingredients in the extract of Radix Polygalae. Our previous studies have indicated that both of DISS and TFSA have neuroprotective effects in different *in vitro* models ([@B13], [@B15], [@B12]). In addition, both can stimulate the expression and phosphorylation of key proteins in the cAMP response element-binding protein (CREB) signaling pathway ([@B19]; [@B8]).

cAMP response element-binding protein with its upstream and downstream effectors is thought to play a role in the pathophysiology of depression as well as in efficacy of antidepressant treatment ([@B21]; [@B23]; [@B26]). A serial of activity-inducible kinases (such as protein kinase C, Ca2+/CaM-dependent kinases II and IV, protein kinase A, ribosomal S6 kinase, AKT, mitogen/stress-activated kinase, and MAPK kinase 2) can increase the phosphorylation of CREB ([@B9]; [@B10]; [@B27]; [@B11]; [@B17]). Meanwhile, CREB-regulated transcription co-activators (CRTCs) can also dramatically increase CREB-mediated transcriptional activity independently of the phosphorylation status of CREB ([@B24]). Both of the above-mentioned mechanisms upregulate the downstream neurotrophic factor (BDNF) and affect neuronal proliferation, synaptic function, and synaptic plasticity.

Synergy may occur when two or more herbal ingredients are combined, which can mutually enhance each other's effect when compared with administration alone ([@B20]). Therefore, we combined DISS and TFSA to determine if such a combination produced an additive or synergistic neuroprotective effect.

In the present study, we specifically aimed to assess the combination effect of two compounds, DISS and TSFA, in mediating neuroprotective effects *in vitro* and to further explore their additive mechanism via CREB pathway \[CRTC1, pCREB (phosphor-CREB), BDNF\]. Our goal was to investigate the potential usefulness of combining candidate active oligosaccharide esters for the treatment of mental disorders, by which we could reduce the risk of adverse effects by lowering their concentrations.

Materials and Methods {#s1}
=====================

Materials
---------

3,6'-Disinapoyl sucrose and TSFA were isolated from Radix Polygalae, identified by a combination of spectral methods (UV, IR, MS, and NMR) and purified by HPLC (purity \>90%). U0126 and LY294002 were purchased from Selleck Chemicals LLC (Houston, TX, USA). Dulbecco's modified Eagle's medium (nutrient mixture F-12; DMEM/F-12) was obtained from Gibco (Carlsbad, CA, USA). Fetal bovine serum (FBS) was supplied by Hyclone (Logan, UT, USA). Polyclonal rabbit antibodies against BDNF, CREB, pCREB, CRTC1, and β-actin were all provided by Bioworld Technology (Atlanta, GA, USA) or Abcam (Burlingame, CA, USA).

Cell Culture
------------

SH-SY5Y human neuroblastoma cells were obtained from the American Type Culture Collection (Rockville, MD, USA) and cultured in DMEM/F-12 supplemented with 10% heat-inactivated FBS and 1% penicillin-steptomycin (50 U/mL). The cells were maintained in a humidified atmosphere with 5% CO~2~ at 37°C. The culture medium was refreshed every other day.

Cell Viability Assay and Synergy Experiments
--------------------------------------------

Cells were seeded into 96-well plates at a density of approximately 2 × 10^3^ cells/well and then grown for 24 h. Subsequently, cells were cultured with serum-free medium (0.1% BSA in growth medium without FBS) for another 24 h and then treated with DISS or TFSA at desired concentrations (15.625--2,000 μM). After 48-h treatment, cell viability was determined by Cell Counting Kit-8 (CCK-8; Keygen Biotech., Nanjing, China). Results were from six independent experiments, and each experiment was run in triplicate. The data were presented as percentage relative to untreated cells. The drug response curve was generated based on the determined relative cell viability, and 50% effective concentration (EC~50~) was measured using software Graphpad Prism5 ([@B25]). EC~50~ of combination was tested on TFSA at a fixed concentration (40 μM) plus DISS at various concentrations (600, 300, 150, 75, 37.5, 18.75 μmol/L). Combination effects of DISS and TFSA treatment were evaluated by calculating the combination index (CI) value as previously reported by Chou ([@B6]). CI = EC~50(DISSplusTFSA)~/EC~50\ (DISSalone)~ + C~TFSA~/EC~50\ (TFSAalone)~. C~TFSA~ was the TFSA concentration used in combination. In this analysis, synergism was defined as follows: CI \> 1.1, antagonism; 1.1 \< CI \< 0.9, additive effect; 0.9 \< CI \< 0.3, synergic effect; and CI \< 0.3, strong synergism.

Inhibition Experiments
----------------------

Briefly, cells were seeded into a 96-well plate or 6-well plate at a density of approximately 3 × 10^3^ cells/well or 1 × 10^4^ cells/well with full growth medium. After 24 h, medium was refreshed by serum-free medium and incubated 24 h. Cells were exposed to 8 mM glutamate (Glu) for 24 h, followed by treatment with DISS (75/150 μM), TFSA (25/50 μM) alone or combinations of DISS and TFSA at desired concentrations with or without antagonists (U0126/LY294002) for 24 or 48 h (assay BNDF mRNA, western blot), and each concentration of the inhibitor was established according to a previous study with minor modifications ([@B16]).

Measurement of NOS and iNOS Activities
--------------------------------------

Cells were seeded into 6-well plates at a density of approximately 1 × 10^4^ cells/well cells and grown for 24 h. Subsequently, cells were exposed to 8 mM Glu for another 24 h. After different treatments for 48 h, cells were collected and re-suspended in PBS. Cell suspension was centrifuged, and the supernatant was collected into EP tubes and then stored at low temperature (0°C). NOS and iNOS activities as well as NO content were determined using a reagent kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China) using an ultraviolet spectrophotometer at a wavelength of 540 nm.

BDNF Expression at the mRNA Level
---------------------------------

Total RNA was extracted from cells using Trizol reagent. RNA concentration was determined using an Eppendorf BioPhotometer plus (Eppendorf, Germany). Subsequently, purified RNA was reversely transcribed into cDNA using iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA) according to the manufacture's instructions. BDNF expression at the mRNA level was assessed by qPCR using SsO Fast Eva Green Supermix (Bio-Rad, Hercules, CA, USA) according to the manufacturer's instructions. GAPDH was selected as the housekeeping gene. The following sequences were used in the study:

1.  BDNF up Primer: GACGGTCACAGTCCTAGAGAA,

2.  BDNF low primer CCTTATGAATCGCCAGCCAAT;

3.  GAPDH up primer ACTTCAACAGAGACACCCACTC,

4.  GAPDH low primer TCTCTCTTCCTCTTGTGCTCTTGC.

Briefly, after an initial denaturation step at 95°C for 30 sec, amplifications were carried out with 40 cycle at a melting temperature of 95°C for 5 sec, an annealing temperature of 60°C for 5 sec, and an extension temperature of 65°C for 5 sec. Standard curves were generated for each gene, and the gene expression at the mRNA level was calculated relative to serial dilution of cDNA as described in Bio-Rad iQ5 System (California, USA). All experiments were conducted in triplicates. Relative expression was estimated using the 2^-ΔΔCt^ method.

Western Blotting
----------------

After 48-h treatment, cells were collected and washed twice with ice-cold PBS. Subsequently, cell pellet was lyzed in lysis buffer (1% Triton, 20 mM Tris--HCl, 150 mM NaCl, 1 mM EDTA, pH 7.5) supplemented with one tablet of complete protease inhibitor cocktail (Roche, Laval, QC, Canada) and phosphatase inhibitor cocktail (Sigma, St. Louis, MO, USA), and the cell lysates were centrifuged at 1,000 *g* for 10 min at 4°C. Total amounts of proteins in each sample were determined by BCA kit, and the protein concentrations of all samples were adjusted to be the same. Supernatants containing 20 μg proteins were separated on 10% SDS-PAGE and electrotransferred onto polyvinylidenedifluoride (PVDF) membranes. Blots were blocked in Tris buffered saline containing 0.1% Tween-20 (TBST) and 5% non-fat-dried milk at room temperature for 1 h. Next, the membranes were incubated with the respective primary antibodies (anti-CREB 1:500, anti-phospho-CREB 1:500, anti-BDNF 1:2,000, and CRTC1 1:10,000) overnight at 4°C. Following three washes with TBST, the blots were incubated with the secondary horseradish peroxidase-conjugated antibody (1:6,000) at room temperature for 1 h, and optical density of protein bands was determined using an image analysis system (Bio-Imaging Analyzer, UVP). All the results of western blot consisted of three independent experiments, and each independent experiment was performed in triplicate.

Statistical Analysis
--------------------

Data were presented as mean ± SD. Comparisons were carried out using one way analysis of variance (ANOVA) followed by Tukey-Kramer's test for *post hoc* analysis. All statistical analyses were performed using ANOVA by the PRISM software (GraphPad software, San Diego, CA, USA). *P* \< 0.05 was considered as statistically significant.

Results
=======

Combination of DISS and TFSA Inhibits Glu-Induced Decrease in Cell Viability
----------------------------------------------------------------------------

**Figure [1](#F1){ref-type="fig"}** shows that the EC~50~ values of DISS and TFSA were 606.4 ± 23.3 μM and 237.8 ± 13.3 μM, respectively. The fixed concentration of 40 μM TFSA in combination was according to EC~20~ of TFSA (40.71 ± 2.47 μM). The EC~50~ of combination of DISS and TFSA was 83.86 ± 1.06 μM. CI value of co-treatment was 0.31, suggesting that combination of DISS and TFSA possessed a synergistic effect. Next, we investigated whether the combination of DISS and TFSA could have an additive or synergistic effect in preventing neuronal damage in SH-SY5Y cells. In order to lower the possible side effects of the compounds according to our previous experience, the concentrations of DISS and TFSA were set to 150/75 μM and 75/50 μM, respectively. The EC~20~ of DISS alone was 214.2 ± 1.23 μM. In combination, we chose 150 or 75 μM DISS that lower than EC~20~ of DISS and increased slightly TFSA concentrations based on EC~20~ of TFSA alone.

![**EC~50~ of combination of DISS (3,6'-Disinapoyl sucrose) and TFSA (tenuifolisideA).** Cells were treated with DISS or TFSA at desired concentrations (15.625--2,000 μM) then cell viability were determined by cell counting kit-8. DISS or TFSA response curve was generated based on the determined relative cell viability, EC~50~ was measured. EC~50~ of combination was tested on TFSA at a fixed concentration (40 μM) plus DISS at various concentrations (600, 300, 150, 75, 37.5, 18.75 μmol/L). The EC~50~ of DISS, TFSA and the combination of DISS and TFSA was 606.4 ± 23.3 μM, 237.8 ± 13.3 μM, and 83.86 ± 1.06 μM, respectively. CI value of combination was 0.31 (CI \< 1 means synergic effect).](fphar-07-00337-g001){#F1}

The Effects of MAPK/ERK1/2 and PI3-K/Akt Inhibitors on the Protective Effects of DISS and TFSA against Glu-Induced Decrease in Cell Viability and Proliferation Rate
--------------------------------------------------------------------------------------------------------------------------------------------------------------------

Based on this Glu-induced decrease in cell activity, the neuronal cytotoxicity of Glu could be partially inhibited by the pretreatment of DISS or TFSA in a dose-dependent manner. More importantly, the co-treatment of TFSA and DISS at two testing doses (75 μM + 25 μM and 150 μM + 25 μM) could produce a significant neuroprotective activity as compared with individual compounds alone, exhibiting increased cell viability from 48% to more than 85%. **Figures [2A,B](#F2){ref-type="fig"}** shows that such a protective effect of DISS at 150 and 75 μM could be blocked by the MAPK/ERK1/2 inhibitor, U0126 (10 μM), but not by the PI3-K inhibitor, LY290042 (20 μM). In contrast, the LY290042, but not U0126, inhibited the neuroprotective effect of TFSA. Moreover, the inhibitory effect of combination of U0126 and LY290042 became even more obvious, showing reduced cell viability from 85% to less than 60% (**Figure [2C](#F2){ref-type="fig"}**).

![**Combination effect of DISS and TFSA on cell viability in SY5Y cells (*n* = 18).** SY5Y cells were exposed to 8 mM Glu for 24 h, followed by combination treatment of DISS and TFSA as well as inhibitors (U0126, LY294002). **(A)** Cells were treated by DISS and inhibitors. **(B)** Cells were treated by TFSA and inhibitors. **(C)** Cells were treated by combination of DISS, TFSA and inhibitors. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 compared with the Glu group. Red ^∗∗^*p* \< 0.01 compared with control group. ^\#^*p* \< 0.05, ^\#^*p* \< 0.001, and red ^\#^*p* \< 0.05 compared with its compound alone.](fphar-07-00337-g002){#F2}

Combination Effects of DISS and TFSA on the Expression of CREB Pathway Related Key Targets
------------------------------------------------------------------------------------------

In order to further understand the mechanism of the combination effect of DISS and TFSA on the neuroprotection, we investigated the expressions of CREB, CRTC1, pCREB, and BDNF. DISS or TFSA alone could induce the protein expression of pCREB/CREB at both doses, and additive effect was observed for the combination of DISS and TFSA (**Figure [3A](#F3){ref-type="fig"}**). In addition, TFSA at 25 μM had no effect on the CRTC1 expression. However, combinations of 25 μM TFSA and 150 or 75 μM DISS both significantly increased the CRTC1 expression (**Figure [3B](#F3){ref-type="fig"}**). Meanwhile, the combinations of DISS and TFSA at different ratios all significantly enhanced the BDNF expression at the mRNA and protein levels (**Figures [3C,D](#F3){ref-type="fig"}**). Moreover, BDNF expression at the mRNA level was induced for more than threefold by combinations of 150 μM DISS and 25 μM TFSA; 75 μM DISS and 50 μM TFSA; or 75 μM DISS and 25 μM TFSA compared with compounds alone (**Figure [3D](#F3){ref-type="fig"}**).

![**Combination effect of DISS and TFSA on pCREB (phosphor-CREB)/CREB (cAMP response element-binding protein), BDNF, and CRTC1 expressions at the protein level as well as BDNF expression at the mRNA level in SY5Y cell (*n* = 18).** SY5Y cells were treated with 75 μM or 150 μM DISS, 25 μM or 75 μM TFSA, or combination of DISS and TFSA for 24 h. **(A,B,C)** Combination effect of DISS and TFSA on pCREB/CREB, CRTC1, and BDNF expressions at the protein level. **(D)** Combination effect of DISS and TFSA on BDNF expression at the mRNA level. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 compared with the control group. ^\#^*p* \< 0.05 and ^\#\#^*p* \< 0.01 compared with its compound alone.](fphar-07-00337-g003){#F3}

The Effects of ERK1/2 and PI-3K Inhibitors Are Involved in the Regulation of CRTC1 and BDNF Expressions by Induced by DISS and TFSA
-----------------------------------------------------------------------------------------------------------------------------------

Considering the various CREB pathways activated by DISS and TFSA, we assessed the signaling mechanisms involved in CRTC1 and BDNF regulation using two inhibitors. **Figure [4](#F4){ref-type="fig"}** reveals that treatment of DISS or TFSA increased the expression of BDNF and CRTC1, but such an increase could be partially attenuated by either U0126 or LY294002. PI3-K inhibitor LY294003 showed a similar but weaker inhibitory effect on DISS-induced CRTC1 expression compared with U0126 (**Figure [4A](#F4){ref-type="fig"}**). The LY294002 decreased the DISS- or TFSA-induced BDNF expression by 47 and 25%, respectively. The ERK1/2 inhibitor U0126 decreased the DISS- or TFSA-induced BDNF expression by 25 and 21%, respectively. (**Figure [4B](#F4){ref-type="fig"}**). A bigger decrease in DISS- or TFSA-induced BDNF expression was caused by LY294003 compared with U0126 (**Figure [4B](#F4){ref-type="fig"}**).

![**Inhibitory effect of ERK1/2 and PI3K on DISS- or TFSA-induced BDNF and CRTC1 expressions in SY5Y cells (*n* = 9).** SY5Y cells were pretreated with 10 μM U0126 or 30 μM LY294002 for 30 min, followed by treatment with 150 μM DISS or 50 μM TFSA for 48 h. **(A)** Expressions of BDNF and CRTC1 were examined by western blotting. **(B)** The expression of BDNF and CRTC1. Data were expressed as mean ± SD. ^∗^*p* \< 0.05 and ^∗∗^*p* \< 0.01 compared with the untreated control group. ^\#^*p* \< 0.05 compared with its compound alone.](fphar-07-00337-g004){#F4}

Combination Effects of DISS and TFSA on tNOS and iNOS Levels
------------------------------------------------------------

To further investigate the additive neuroprotection of DISS and TFSA against the Glu-induced cell injury, we examined the levels of tNOS and iNOS, which play an important role in cell apoptosis or neurodegenerative disorders ([@B4]; [@B29]). **Figure [5](#F5){ref-type="fig"}** shows that Glu significantly increased the levels of tNOS and iNOS. DISS or TFSA treatment alone decreased the intracellular level of tNOS by 4--8%, but showed no effect on iNOS level. However, co-treatment of DISS and TFSA significantly decreased such an elevation of tNOS and iNOS levels by 29.3 and 40.5%, respectively. These results suggested that the combination of DISS and TFSA could more vigorously inhibit the Glu-induced NO overproduction.

![**Combination effect of DISS and TFSA on levels of tNOS and iNOS in SY5Y cells (*n* = 18).** SY5Y cells were exposed to Glu for 24 h, after which Glu was changed to DISS and TFSA combination medium for 48 h. Levels of tNOS and iNOS were determined by a reagent kit ^∗∗^*p* \< 0.01 compared with Glu; ^∗∗^*p* \< 0.01 compared with the control; ^∗^*p* \< 0.05, ^\#^*p* \< 0.01 compared with its compound alone.](fphar-07-00337-g005){#F5}

Discussion
==========

The combination strategy offers a series of potential advantages, including less side effects and a more rapid or effective clinical response. In the current study, combination of the two active oligosaccharide esters demonstrated additive neuroprotective effects against Glu-induced damage. Compared with DISS or TFSA alone, their combination also significantly increased the expressions of pCREB, CRTC1, and BDNF.

Several studies have shown that DISS and TFSA play an antidepressant and neuroprotective role. DISS protects human neuroblastoma cells (SH-SY5Y) from Glu- or H~2~O~2~-induced damage, and DISS-mediated regulation of BDNF expression is associated with CREB-mediated transcription of BDNF and upstream activation of ERK1/2 and CaMKII ([@B16]). In our previous study, DISS possesses antidepressant-like properties, and its underlying mechanism might also be related to effects on hippocampal neuroplasticity gene BDNF ([@B13]). TFSA, with the similar chemical structure, can also promote the proliferation of C6 glioma cells, and its mechanism has been related to TrkB/BDNF/ERK and TrkB/BDNF/PI3-K signaling pathways ([@B8]).

Over the past decades, studies have suggested that neurotrophins and related signaling cascades are involved in the pathophysiology of depression. CREB upregulation may activate downstream targets, such as BDNF, after antidepressant treatment. In fact, a series of elegant studies have also shown that PI-3K/Akt and MAPK/Erk pathways, which can promote neuronal growth and survival, are two key signaling cascades regulating CREB/BDNF activation ([@B5]). Meanwhile, CRTC1, as another essential gene for long-term synaptic plasticity and synaptic development, also plays an important role in CREB-dependent gene transcription ([@B28]).

In the present study, we, for the first time, showed that DISS and TFSA possessed additive or synergistic protective effects on nerve regeneration *in vitro*. Additive effects were observed on cell viability, pCREB/CREB, BDNF, CRTC1, tNOS, and iNOS activities, synergistic effects were observed on BDNF mRNA. We adopted kinase inhibitors of U0126 and LY294002 to explore the mechanisms. It showed that combination of DISS and TFSA exerted an additive effect on CREB phosphorylation, and expressions of CRTC1 and BDNF at the protein level. **Figure [6](#F6){ref-type="fig"}** illustrates that DISS and TFSA activated the PI-3K/Akt and MAPK/Erk pathways, leading to stronger activation of the downstream CREB phosphorylation and simultaneously increased CRTC1 expression, and both of them were beneficial to the transcription of BDNF, which could eventually promote the neuronal survival.

![**The graph of DISS and TFSA synergistically activated the PI-3K/Akt and MAPK/ERK pathways**.](fphar-07-00337-g006){#F6}

In additional to the role in CREB/BDNF regulation, NO is an important messenger and effector molecule that possesses neurotransmitter and neuromodulator functions and participates in physiological and pathological activities. NO, together with iNOS and nNOS, is well known to be involved in the pathogenesis of neurodegenerative disorders ([@B5]; [@B7]; [@B18]). Both N-methyl-[D]{.smallcaps}-aspartate receptor activation and Glu can induce the iNOS expression and NO production, subsequently leading to excessive damage caused by free radicals ([@B1]; [@B7]). Our results indicated that the levels of iNOS and tNOS were significantly increased in Glu-treated SY5Y cells, while combination of DISS and TFSA could ameliorate such Glu-induced NO production and iNOS overdosage, suggesting that the combination effect on neuroprotection was also involved in regulation of iNOS and tNOS activities.

Conclusion
==========

Combination of DISS and TFSA activated CREB-mediated MAPK and PI-3K cascades and induced the BDNF expression, revealing the underlying molecular mechanism of their additive neuroprotective effects. Our findings suggested the potential of a novel candidate oligosaccharide ester for the development of natural supplements against depression. Both DISS and TFSA are active oligosaccharide ester components found in the root of Polygala tenuifolia Willd. Our previous study showed that DISS has anti-depressive activity *in vivo* ([@B13]). The molecular weights of DISS and TFSA are 752 and 682 kDa, respectively. And both of them are fat-soluble. However, it remains unclear whether DISS, TFSA or its metabolites could pass the blood brain barrier. In our future study, we will further explore their additive or synergistic effects on mental disorder in animal models and investigate whether they can pass the blood brain barrier.
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